Cathepsin L1 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)- Pipeline Review, H2 2019’, provides in depth analysis on Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease under development targeting Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

– The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Mateon Therapeutics Inc

Phelix Therapeutics LLC

Virobay Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Overview

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Companies Involved in Therapeutics Development

Mateon Therapeutics Inc

Phelix Therapeutics LLC

Virobay Inc

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Drug Profiles

Drugs to Inhibit Cathepsin L for Coronaviridae Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-207 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-420 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-94 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Dormant Products

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) Product Development Milestones

Featured News & Press Releases

Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017

Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Mateon Therapeutics Inc, H2 2019

Pipeline by Phelix Therapeutics LLC, H2 2019

Pipeline by Virobay Inc, H2 2019

Dormant Projects, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports